Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

ChemoMetec A/S (CHEMM)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
286.60 +4.20    +1.49%
26/04 - Closed. Currency in DKK ( Disclaimer )
Type:  Equity
Market:  Denmark
ISIN:  DK0060055861 
S/N:  17402479
  • Volume: 54,112
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 282.20 - 289.80
ChemoMetec 286.60 +4.20 +1.49%

CHEMM Balance Sheet

 
Featured here, the Balance Sheet for ChemoMetec A/S, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Collapse All
Period Ending: 2023
31/12
 2023
30/09
 2023
30/06
 2023
31/03
Total Current Assets 420.64 420.64 492.66 492.66
Cash and Short Term Investments 232.15 232.15 316.57 316.57
Cash - - - -
Cash & Equivalents 232.15 232.15 316.57 316.57
Short Term Investments - - - -
Total Receivables, Net 67.34 67.34 59.74 59.74
Accounts Receivables - Trade, Net 59.86 59.86 54.83 54.83
Total Inventory 117.78 117.78 112.64 112.64
Prepaid Expenses 3.37 3.37 3.71 3.71
Other Current Assets, Total - - - -
Total Assets 593.51 593.51 657.98 657.98
Property/Plant/Equipment, Total - Net 85.17 85.17 82.68 82.68
Property/Plant/Equipment, Total - Gross 162.16 162.16 155.06 155.06
Accumulated Depreciation, Total -76.98 -76.98 -72.37 -72.37
Goodwill, Net - - - -
Intangibles, Net 87.17 87.17 79.66 79.66
Long Term Investments - - - -
Note Receivable - Long Term 7.48 7.48 4.91 4.91
Other Long Term Assets, Total 0.312 0.312 0.318 0.318
Other Assets, Total 50.65 50.65 55.54 55.54
Total Current Liabilities 89.92 89.92 119.19 119.19
Accounts Payable 11.63 11.63 17.55 17.55
Payable/Accrued - - - -
Accrued Expenses - - 8.2 8.2
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 3.34 3.34 3.52 3.52
Other Current liabilities, Total 74.95 74.95 89.92 89.92
Total Liabilities 94.78 94.78 124.93 124.93
Total Long Term Debt 2.61 2.61 3.64 3.64
Long Term Debt - - - -
Capital Lease Obligations 2.61 2.61 3.64 3.64
Deferred Income Tax - - - -
Minority Interest - - - -
Other Liabilities, Total 1.14 2.25 2.1 2.1
Total Equity 498.73 498.73 533.04 533.04
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 17.4 17.4 17.4 17.4
Additional Paid-In Capital - - - -
Retained Earnings (Accumulated Deficit) 481.31 481.31 515.62 515.62
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 0.017 0.017 0.018 0.018
Total Liabilities & Shareholders' Equity 593.51 593.51 657.98 657.98
Total Common Shares Outstanding 17.4 17.4 17.4 17.4
Total Preferred Shares Outstanding - - - -
* In Millions of DKK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

CHEMM Comments

Write your thoughts about ChemoMetec A/S
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
The Note
TheNote Jan 23, 2023 4:36AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Twitter - Chemometec - Come and meet us at booth no. 19 at the CAR-TCR Summit Europe, which will be held February 21 – 23, 2023, in London, UK.
Reply
0 0
Report
The Note
TheNote Jan 17, 2023 7:36PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Cordis - Horizon - Circular Vision - EU project with 4 million Euro to be presented 31. March 2024.
Reply
0 0
Report
The Note
TheNote Jan 17, 2023 6:24PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Chemometec presents for the tasks - NC202, Xcytomatic 40 and Xcyto5 and Xcyto10. The latter used in the patent taking of patterns.Eu is a very active contributor and the first cancer desease is under research. The results to be presented 2024 in collaboration with Roche Diagnostics.
Reply
0 0
Report
The Note
TheNote Jan 17, 2023 6:07PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Cirkular DNA - a biomarker - ready as diagnostic tool in 2024 ?Circular DNA is emerging as a novel biomarker for many types of cancer and inflammatory disorders. However, we lack the technology for detecting circular DNA and for generating appropriate disease models. To address this problem, the EU-funded CIRCULAR VISION project will use lung cancer and inflammatory bowel disease to investigate the link between disease and circular DNA. Scientists will combine microfluidics, DNA sequencing and bioinformatics to identify new biomarkers and develop novel approaches for cancer diagnosis. The generated technology will pave the way for future research and drug development in the field.
Reply
0 0
Report
The Note
TheNote Jan 17, 2023 5:50PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
2022 was a record year for the approval of never-before-authorized gene therapies, with three new therapies approved to treat rare diseases and another approved to treat bladder cancer. Additionally, five therapies that had already been approved in the US or Europe were authorized for the first time in a new geography or for another indication.But this is just the initial swell of the coming wave. As of this writing, as many as 13 brand new cell or gene therapies could be approved for use in the US, Europe, or both by the end of 2023. We are in reach of the FDA’s often-cited 2019 prediction that it would approve 10-20 new cell and gene therapies a year by 2025.
Reply
0 0
Report
The Note
TheNote Jan 17, 2023 5:48PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
There are now six FDA-approved CAR-T cell therapies available to patients in both the US and Europe to treat various blood cancers. They are but one part of a growing set of promising cell and gene therapies to address rare and prevalent conditions.There are over 2,000 clinical trials happening today, with 200 in Phase III – a wave of hope for patients waiting on durable, possibly curative treatments. But investment, policy, and regulatory challenges remain for the sector, and many patients will not benefit unless we modernize our approach to health care.
Reply
0 0
Report
The Note
TheNote Jan 17, 2023 5:09PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Report headlines to read, .. search for .. CAR-T Therapy market is projected to grow at a CAGR of 42.95% by 2032: Visiongain Reports Ltd
Reply
0 0
Report
The Note
TheNote Jan 17, 2023 2:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Weekly macd once again pointing upwards. The astonishing growth in Car-t and Gene therapeutics with + 40 % continues. The revolution in cirkular DNA diagnostics methods will in 2024 contribute to the growth. Together with the danish universities and ROCHE DIAGNOSTICS methods in cancer diagnostics and residual control will revolutionize medical timeframes a survivability. Cirkular DNA is to be found in 50 % of all cancer expressions. Due to their high technology and vast patenting Chemometec is ready to profit from these revolutionary methods. Read more at Chemotetec.dk
Reply
0 0
Report
The Note
TheNote Feb 08, 2022 6:49AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Confirmed break up from negative trade channel and weekly macd accelerating. Chart: https://invst.ly/xc7vy
Reply
0 0
Report
The Note
TheNote Feb 08, 2022 6:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
First halv year .. Interim .. growth 58 % and ebitda growth from 50 to 55 %. Preparing to launch the first automatick industrial scale advanced cell counter.
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email